- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01351779
The Effect of Body Posture on Intraocular Pressure in Progressive Glaucoma
May 9, 2011 updated by: University of Toronto
Glaucoma is a condition where the optic nerve (the nerve responsible for sight) shows progressive damage with characteristic loss of visual field.
Glaucoma is very commonly associated with raised pressure in the eye (intraocular pressure [IOP]).
IOP has been shown to increase when lying down in normal subjects as well as patients with glaucoma.
It is possible that this effect can make glaucoma worse.
This study is designed to investigate the effect of body posture (particularly when sleeping) on the IOP fluctuation in the eye.
Each patient will be required to attend for 2 separate 24 hour visits.
On one visit the patient will be required to sleep flat and on the other visit at a 30° head up sleeping position.
During this time the patient will be required to wear a soft contact lens (SENSIMED Triggerfish®) which has a special sensor on it that monitors the IOP continuously.
The IOP measurements are wirelessly transmitted to a recorder.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Recruiting
- Toronto Western Hospital
-
Contact:
- Graham Prof Trope, PhD, FRCSC
- Phone Number: 4166035317
- Email: raham.Trope@uhn.on.ca
-
Principal Investigator:
- Graham E Trope, PhD, FRCSC
-
Sub-Investigator:
- Yvonne M Buys, MD, FRCSC
-
Sub-Investigator:
- Hussain Patel, MD
-
Sub-Investigator:
- John Flanagan, DO, PhD
-
Sub-Investigator:
- Colin Shapiro, MD, PhD
-
Sub-Investigator:
- Farzana Jahan, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Glaucoma clinic patients
Description
Inclusion Criteria:
- signed informed consent
- diagnosis of primary open angle glaucoma (POAG) or normal tension glaucoma (NTG) that is progressing based on recent or recurrent optic disc hemorrhage
- age 18-85 years
- not more than 4 diopters of spherical equivalent or 2 diopters of cylinder equivalent in study eye
- stable anti-glaucoma treatment for 4 weeks before first session
- for women of childbearing potential, adequate contraception
Exclusion Criteria:
- unwilling or unable to sleep in a flat or 30 degrees head up position
- ocular surgery in previous 3 months
- corneal or conjunctival abnormality
- wear of full frame metallic glasses during monitoring session
- severe dry eye
- secondary forms of glaucoma
- allergy to corneal anaesthesia
- patients with contraindications for contact lens wear
- pregnancy and lactation
- patients unable to understand the character and individual consequences of the investigation
- simultaneous participation in other research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Progressive glaucoma
Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraocular pressure changes that occur during sleep and with changes in body posture
Time Frame: 24 hours
|
The intraocular pressure will be continuously monitored with a wireless contact lens sensor device over a 24 hour period
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of side effects or adverse effects that occur while subjects are wearing the contact lens device
Time Frame: 24 hours
|
Patients will be monitored for contact lens related side effects or adverse effects that occur during the monitoring session.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Anticipated)
May 1, 2012
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
May 9, 2011
First Submitted That Met QC Criteria
May 9, 2011
First Posted (Estimate)
May 11, 2011
Study Record Updates
Last Update Posted (Estimate)
May 11, 2011
Last Update Submitted That Met QC Criteria
May 9, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-0844-A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Hospices Civils de LyonRecruitingOpen-angle Glaucoma | Glaucoma Eye | Pigmentary Glaucoma | Closed-Angle Glaucoma | Pseudo Exfoliative SyndromeFrance
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Isfahan University of Medical SciencesActive, not recruitingAngle Closure Glaucoma | Glaucoma EyeIran
-
University of MiamiAbbVieRecruitingOcular Hypertension | Glaucoma | Open-Angle Glaucoma | Glaucoma SuspectUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Ngoc Nguyen Inc.Alcon ResearchNot yet recruitingGlaucoma | Glaucoma, Open Angle | Open Angle Glaucoma (OAG) | Normal Tension Glaucoma (NTG)United States
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama